StabiCaps addresses crosslinking, a common challenge in the dissolution of softgels that results in slower or incomplete release of nutrients or pharmaceutical ingredients contained within the capsule.
Crosslinking occurs when softgels are exposed to specific active compounds or poor storage conditions causing molecular bonds — that limit or prevent dissolution of the capsule — to form within the capsule shell.
In May 2022, the company also received a patent from the European Patent Office (EPO) for StabiCaps for all major European countries.
“StabiCaps is an essential innovation for softgel manufacturers because gelatin is a primary ingredient,” said Pierre-Albert Thomas, Rousselot Functional Ingredients Director.
“With this new patent, softgel manufacturers in the US can unlock the benefits of StabiCaps gelatin technology to produce high-quality softgels with longer shelf stability and improved efficacy for customers.”
Softgels are among preferred dosage formats for numerous benefits, including ease of swallowing and odour- and taste-masking capabilities. The global softgels market is projected to grow at a compound annual growth rate of 4.3% from 2023 to 2033.
StabiCaps is part of Rousselot’s broader portfolio of world-class gelatin solutions for the nutra- and pharmaceutical markets, which also include SiMoGel, an innovative technology that allows for starch-free gummy production.
